SlideShare a Scribd company logo
POLIOMYELITIS
Kuldeep Vyas
Asst. Prof. Community Health
Nursing1Kuldeep Vyas M.Sc. N. CHN
Introduction
 Greek poliós= "grey", myelós= marrow, and the suffix -
itis= inflammation
 First described by British physician Micheal Underwood in 1799
referring to it as "debility of the lower extremities.“
 A viral infection most often recognized by acute onset of flaccid
paralysis.
 Primarily an infection of human alimentary tract, but may infect
CNS in very small no. (i.e <1%)
 Infection results in a spectrum of clinical manifestations……
2Kuldeep Vyas M.Sc. N. CHN
3Kuldeep Vyas M.Sc. N. CHN
Problem statement
World
 A worldwide problem in pre vaccination era
 With the wide use of polio vaccine from 1954 disease
being eliminated from most of the developed countries
 In 1988 WHA resolved to eradicate the disease globally
 Since than no. of endemic countries reduced from 125 in
1988 to 3 in 2012.
 Reported cases worldwide decreased by 51% (1352 in
2010 to 650 in 2011)
4Kuldeep Vyas M.Sc. N. CHN
Cont…
India
No reported cases since January 2011 (last
case reported in 13th Jan 2011, Howrah,
West Bengal)
Considered polio-free since February 2012
Attained the status of eradication in 13th
January 2014
5Kuldeep Vyas M.Sc. N. CHN
Epidemiology
6Kuldeep Vyas M.Sc. N. CHN
Agent factors
Agent
Poliovirus: belongs to “Picorna” viruses which are
small RNA-containing viruses.
Three serotypes- 1, 2 & 3 giving no cross
immunity
Long survival in environment….lives upto 4hours
in water and 6 hours in faeces in cold
enviornment.
Readily destroyed by heat (e.g. pasteurization of
milk, and chlorination of water). 7Kuldeep Vyas M.Sc. N. CHN
Reservoir of infection
 Man is the only reservoir of infection of poliomyelitis.
 Man: cases and carriers
 Cases: all clinical forms of disease
 Most of the infections are subclinical- dominant role in spread of
infection
 Estimated subclinical infection ranges from 75 to 1000 per clinical case
 No chronic cases or animal sources documented
Foci of infection
 Pharynx: the virus is found in the oropharyngeal secretions.
 Small intestine: the virus finds exit in stools.
8Kuldeep Vyas M.Sc. N. CHN
Modes of transmission
Since foci of infection are the throat and small intestines,
poliomyelitis spreads by two routes:
Oral-oral infection: direct droplet infection
Faeco-oral infection:
– Through contaminated foods. Vehicles include milk, water, or any
others that may be contaminated by handling, flies, dust….
– Hand to mouth infection.
Polio virus has the ability to survive in cold environments.
Overcrowding and poor sanitation provide opportunities for
exposure to infection
9Kuldeep Vyas M.Sc. N. CHN
Period of communicability
 Estimated to about 2 weeks
 Cases: 7 to 10 days before and after the onset of symptoms.
 Virus is excreted commonly for 2 to 3 weeks, sometimes as
long as 3 to 4 months in faeces.
 In polio cases, infectivity in the pharyngeal foci is around one
week, and in the intestinal foci 6-8 weeks.
Incubation Period: 7-14 days
10Kuldeep Vyas M.Sc. N. CHN
Host factors
Age:
 All age groups; children(6 MONTHS TO 3 YEARS most susceptible)
 more than 95% reported in infancy and childhood with over 50% of them
in infancy.
Sex:
 no sex ratio differences, but in some countries, males are infected more
frequently than females in a ratio 3:1.
Risk factors:
 Fatigue, trauma,im injections, tonsillectomy, immunizing agents like alum
containing DPT vaccine and excessive muscular exercise…
Immunity:
 Immunity by maternal antibodies till the age of 6months
 Immunity conferred by natural infection fairly solid but doesn’t protects
against the reinfection by other strains
11Kuldeep Vyas M.Sc. N. CHN
Environmental factors
Rainy season (june to september)
Environmental sources- food, flies and water
Overcrowding and poor sanitation-
oppourtinities
12Kuldeep Vyas M.Sc. N. CHN
Clinical spectrum
13Kuldeep Vyas M.Sc. N. CHN
Inapparent infection
 Occurs approximately in 91-96% of poliovirus infection.
 Incidence is more than 75 to 1000 times the clinical
cases.
 No clinical manifestations, but infection is associated
with acquired immunity.
 Recognition only by virus isolation or rising antibody titre.
14Kuldeep Vyas M.Sc. N. CHN
Clinical poliomyelitis
Abortive polio (minor illness):
 Occurs approximately in 4-8% of the infection.
 Causes only a mild or self limiting illness due to
viraemia.
 Mild systemic manifestations for 1-2 days
 Some abortive cases so mild to pass unnoticed.
 Patient recovers quickly.
 Manifestations:
 Moderate fever
 Upper respiratory manifestations: pharyngitis and sore throat
 Gastrointestinal manifestations: vomiting, abdominal pain,
and diarrhea.
15Kuldeep Vyas M.Sc. N. CHN
Cont…..
Involvement of the CNS (major illness):
 Affects a small proportion of the clinical cases
 Takes two forms: Non-paralytic and Paralytic polio.
Non paralytic polio:
 Occurs approximately in one per cent of all infections.
 Presenting features are stiffness and pain in neck and back.
 Disease lasts for 2-10 days.
 Recovery is rapid.
16Kuldeep Vyas M.Sc. N. CHN
Cont…
Paralytic polio:
 Occurs in less then one per cent of infections.
 The virus enters the CNS and causes varying degree of disability
with destruction of the motor nerve cells, but not the sensory
nerve cells.
 Forms: spinal, bulbar, and bulbospinal.
 Paralysis usually appears within 4 days (around 7-10 days from
onset of disease).
 History of fever at the time of paralysis- suggestive of polio.
 Progression of paralysis reaches maximum by 4th day (4-7 days)
17Kuldeep Vyas M.Sc. N. CHN
Cont….
 Other symptoms- malaise, anorexia, vommiting, headache, sore
throat, constipation and headache.
 Signs of meningeal irritation
 Tripod sign may be present
 Assymetrical, patchy flaccid paralysis, of descending type
affecting the proximal group of muscle the most
 Deep tendon reflexes (DTR) deminished before the the onset of
paralysis.
 Cranial nerve involvement seen in bulbar and bulbospinal
paralytic poliomyelitis
 Facial assymetry, difficulty in swallowing weakness of voice;
respiratory insuffiency may lead to death
18Kuldeep Vyas M.Sc. N. CHN
19Kuldeep Vyas M.Sc. N. CHN
Spinal polio
Different spinal nerves are involved
Injury of the anterior horn cells of the spinal cord
causing tenderness, weakness, and flaccid
paralysis of the corresponding striated muscles.
The lower limbs are the most commonly affected.
20Kuldeep Vyas M.Sc. N. CHN
Bulbar polio
Nuclei of the cranial nerves are involved, causing
weakness of the supplied muscles, and maybe
encephalitis.
Bulbar manifestations include dysphagia, nasal voice,
fluid regurgitation from the nose, difficult chewing, facial
weakness and diplopia
Paralysis of the muscles of respiration is the most
serious life-threatening manifestation.
Bulbospinal polio
 Combination of both spinal and bulbar forms
21Kuldeep Vyas M.Sc. N. CHN
Polio infection
Polio infection
Inapparent infection Clinical poliomyelitis
Abortive polio Involvement of CNS
(minor illness) (major illness)
Paralytic
polio
Non-paralytic
polio
Spinal polio
Bulbar polio
Bulbospinal polio
22Kuldeep Vyas M.Sc. N. CHN
Complications and case fatality
 Respiratory complications: pneumonia, pulmonary edema
 Cardiovascular complications: myocarditis, cor pulmonale.
 Late complications: soft tissue and bone deformities,
osteoporosis, and chronic distension of the colon.
 Case fatality: varies from 1% to 10% according to the form
of disease (higher in bulbar), complications and age (
fatality increases with age).
23Kuldeep Vyas M.Sc. N. CHN
 Polio is caused by a virus called polio virus
24Kuldeep Vyas M.Sc. N. CHN
Virus gets
into the body
by mouth
Then moves to
GI Track
towards
intestine
Multiplies
Passes into
the blood
Reaches the
spinal cord
Attacks the
nerves
Destruction of
motor neurons
of brain stem
Result in
polio
paralysis
25Kuldeep Vyas M.Sc. N. CHN
Diagnosis and laboratory testing
Laboratory studies critical to rule out or confirm the
diagnosis of paralytic poliomyelitis.
 Virus isolation
 The likelihood of poliovirus isolation is highest from stool
specimens,
 Intermediate from pharyngeal swabs, and very low from blood
or spinal fluid.
 Serologic testing
A four-fold titer rise between the acute and convalescent
specimens suggests poliovirus infection.
26Kuldeep Vyas M.Sc. N. CHN
Prevention
General prevention:
Health promotion through environmental
sanitation.
Health education (modes of spread,
protective value of vaccination).
27Kuldeep Vyas M.Sc. N. CHN
Cont….
Seroprophylaxis by immunoglobulins:
Not a practical way of giving protection
because it must be given either or before or
very shortly after exposure to infection.
Dose-(0.25-0.3 ml/kg of body weight).
Immunized status after a few weeks
28Kuldeep Vyas M.Sc. N. CHN
Active immunization
Inactivated (Salk) vaccine (FIPV)
 Contains 3 serotypes of vaccine virus
 Route of administration- Intra-dermal: Right upper arm .
 Schedule
 First dose given at the age of 6 weeks
 Second dose given at the 14 weeks of age
 Intra dermal two fractional dose of : 0.1 ml
 Highly effective in producing immunity to poliovirus
 >90% immune after 1 doses
 >99% immune after 2 doses
 Duration of immunity not known with certainty
29Kuldeep Vyas M.Sc. N. CHN
Cont…
Oral (Sabin) Polio Vaccine
 Contains 3 serotypes of vaccine virus
 Route of administration- Oral.
 Schedule
 Zero dose vaccination recommended in hospital delivery
 First dose given at the age of 6 weeks
 Next 2 doses 10 weeks
 3rd dose at 14 weeks
 2 drops
 Highly effective in producing immunity to poliovirus
 50% immune after 1 dose
 >95% immune after 3 doses
 Immunity probably lifelong
 Shed in stool for up to 6 weeks following vaccination
30Kuldeep Vyas M.Sc. N. CHN
31Kuldeep Vyas M.Sc. N. CHN
Salk versus Sabin vaccine
32Kuldeep Vyas M.Sc. N. CHN
ORAL POLIO VACCINE
OPV
INACTIVATED POLIO
VACCINE IPV
Albert sabin develop
sabin vaccine
Jonas salk developed salk
vaccine
Live, attenuated
(weakened) virus
Killed virus
Administered by drops Administered by injection
Highly successful in
reducing transmission in
developing countries as
part of eradication
strategy
Highly effective and safe;
Used in developed countries
Inexpensive Expensive
33Kuldeep Vyas M.Sc. N. CHN
Easy to administer Requires trained health care
worker
Provides humoral, mucosal
and gut immunity
Provides humoral immunity
Prevents paralysis and
prevents re-infection
Prevents paralysis but does
not prevent re-infection
Dose = 2 drops Dose = 0.5 ml
Recommended storage
temperature= -15֯C to -
25֯C
Storage temperature= +2֯C
to +8֯C
34Kuldeep Vyas M.Sc. N. CHN
Epidemiological Investigations
Epidemic
 Occurrence of 2 or more local cases caused by the same virus in any
4-weeks period
 Sample of faeces to be collected from all the cases and suspected
cases and subjected to lab testing
 If possible, paired sera to be tested
– First specimen at the clinical suspicion
– Second at the period of convalescence
 An increase in antibody titre provides confirmatory evidence
 OPV should be provided to all persons over 6 weeks age who are not
completely immunize de or immune status unknown in the epidemic
area
35Kuldeep Vyas M.Sc. N. CHN
Thank you…
36Kuldeep Vyas M.Sc. N. CHN

More Related Content

What's hot

Polio
PolioPolio
Japanese encephalitis
Japanese encephalitis Japanese encephalitis
Japanese encephalitis
Nikkin T
 
Yellow fever
Yellow feverYellow fever
Yellow fever
Soumya Ranjan Parida
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
Sidra cheema
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
Ekta Patel
 
MEASLES, MUMPS & RUBELLA
MEASLES, MUMPS & RUBELLAMEASLES, MUMPS & RUBELLA
MEASLES, MUMPS & RUBELLA
mgmcricommunitymed
 
Measles
MeaslesMeasles
Measles
swati shikha
 
Rabies Powerpoint Presentation aerophobia, dog bite prophylaxis, hydrophobia,...
Rabies Powerpoint Presentation aerophobia, dog bite prophylaxis, hydrophobia,...Rabies Powerpoint Presentation aerophobia, dog bite prophylaxis, hydrophobia,...
Rabies Powerpoint Presentation aerophobia, dog bite prophylaxis, hydrophobia,...
Dr Sujith Chadala
 
‘Poliomyeliti’ or Polio
‘Poliomyeliti’ or Polio‘Poliomyeliti’ or Polio
pathogenesis of covid-19
pathogenesis of covid-19pathogenesis of covid-19
pathogenesis of covid-19
MicroShamim
 
Polio
Polio Polio
japanese encephalitis
japanese encephalitisjapanese encephalitis
japanese encephalitis
Pallab Nath
 
Rubella (German Measles)
Rubella (German Measles)Rubella (German Measles)
Rubella (German Measles)
KULDEEP VYAS
 
Poliomyelitis- cause, pathology, affected parts, treatment
Poliomyelitis- cause, pathology, affected parts, treatmentPoliomyelitis- cause, pathology, affected parts, treatment
Poliomyelitis- cause, pathology, affected parts, treatment
Mmantthan Purohit
 
Japanese encephalitis
Japanese encephalitisJapanese encephalitis
Japanese encephalitis
Harivansh Chopra
 
Herd immunity
Herd immunityHerd immunity
Herd immunity
Archit Khardenavis
 

What's hot (20)

Polio
PolioPolio
Polio
 
Japanese encephalitis
Japanese encephalitis Japanese encephalitis
Japanese encephalitis
 
Yellow fever
Yellow feverYellow fever
Yellow fever
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
MEASLES, MUMPS & RUBELLA
MEASLES, MUMPS & RUBELLAMEASLES, MUMPS & RUBELLA
MEASLES, MUMPS & RUBELLA
 
Measles
MeaslesMeasles
Measles
 
Rabies Powerpoint Presentation aerophobia, dog bite prophylaxis, hydrophobia,...
Rabies Powerpoint Presentation aerophobia, dog bite prophylaxis, hydrophobia,...Rabies Powerpoint Presentation aerophobia, dog bite prophylaxis, hydrophobia,...
Rabies Powerpoint Presentation aerophobia, dog bite prophylaxis, hydrophobia,...
 
‘Poliomyeliti’ or Polio
‘Poliomyeliti’ or Polio‘Poliomyeliti’ or Polio
‘Poliomyeliti’ or Polio
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
pathogenesis of covid-19
pathogenesis of covid-19pathogenesis of covid-19
pathogenesis of covid-19
 
Polio
Polio Polio
Polio
 
Polio
PolioPolio
Polio
 
japanese encephalitis
japanese encephalitisjapanese encephalitis
japanese encephalitis
 
Rubella (German Measles)
Rubella (German Measles)Rubella (German Measles)
Rubella (German Measles)
 
Herpesviruses
HerpesvirusesHerpesviruses
Herpesviruses
 
Poliomyelitis- cause, pathology, affected parts, treatment
Poliomyelitis- cause, pathology, affected parts, treatmentPoliomyelitis- cause, pathology, affected parts, treatment
Poliomyelitis- cause, pathology, affected parts, treatment
 
Japanese encephalitis
Japanese encephalitisJapanese encephalitis
Japanese encephalitis
 
Herd immunity
Herd immunityHerd immunity
Herd immunity
 

Similar to Poliomyelitis

Poliomyelitis
Poliomyelitis Poliomyelitis
Poliomyelitis
Dr. Saurabh Agrawal
 
communicable disease (3).pptx
communicable disease  (3).pptxcommunicable disease  (3).pptx
communicable disease (3).pptx
SudhaYadav664582
 
Polio
PolioPolio
Polio
Sudhir Ben
 
6 october -Poliomyelitis -.ppt
6 october -Poliomyelitis -.ppt6 october -Poliomyelitis -.ppt
6 october -Poliomyelitis -.ppt
Drmayuribhise
 
4C. VIRAL CNS INFECTIONS -POLIO, RABIES.pptx
4C. VIRAL CNS INFECTIONS -POLIO, RABIES.pptx4C. VIRAL CNS INFECTIONS -POLIO, RABIES.pptx
4C. VIRAL CNS INFECTIONS -POLIO, RABIES.pptx
StanleyOdira
 
routine immunization in india( from gov.in) .ppt
routine immunization in india( from gov.in) .pptroutine immunization in india( from gov.in) .ppt
routine immunization in india( from gov.in) .ppt
SauravKumar927915
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
Hafsa Maryam
 
EPIDEMIOLOGY – COMMUNICABLE DISEASE.pptx
EPIDEMIOLOGY – COMMUNICABLE DISEASE.pptxEPIDEMIOLOGY – COMMUNICABLE DISEASE.pptx
EPIDEMIOLOGY – COMMUNICABLE DISEASE.pptx
Niranjani sakthivel
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitisnonah4444
 
MEASLES - THEORY.ppt
MEASLES - THEORY.pptMEASLES - THEORY.ppt
MEASLES - THEORY.ppt
mousaderhem1
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
Himangshu Sharma
 
7.Poliomyelitis (1).ppt7.Poliomyelitis (1)
7.Poliomyelitis (1).ppt7.Poliomyelitis (1)7.Poliomyelitis (1).ppt7.Poliomyelitis (1)
7.Poliomyelitis (1).ppt7.Poliomyelitis (1)
AbdulGhayur1
 
Acute flaccid paralysis
Acute flaccid paralysisAcute flaccid paralysis
Acute flaccid paralysis
Magdy Shafik M. Ramadan
 
Surface infection
Surface infectionSurface infection
Surface infection
tulu2015
 
Geriatric health communicable diseases and Egypt
Geriatric health communicable diseases and EgyptGeriatric health communicable diseases and Egypt
Geriatric health communicable diseases and Egypt
Hatem Refaat El-Sheemy
 
ANNUAHREE's presentation.pptx
ANNUAHREE's presentation.pptxANNUAHREE's presentation.pptx
ANNUAHREE's presentation.pptx
annushree9
 
Meningococcal meningitis
Meningococcal meningitisMeningococcal meningitis
Meningococcal meningitisamitakashyap1
 
Poliomyelitis in english
Poliomyelitis in englishPoliomyelitis in english
Poliomyelitis in english
MY STUDENT SUPPORT SYSTEM .
 

Similar to Poliomyelitis (20)

Poliomyelitis
Poliomyelitis Poliomyelitis
Poliomyelitis
 
communicable disease (3).pptx
communicable disease  (3).pptxcommunicable disease  (3).pptx
communicable disease (3).pptx
 
Polio
PolioPolio
Polio
 
6 october -Poliomyelitis -.ppt
6 october -Poliomyelitis -.ppt6 october -Poliomyelitis -.ppt
6 october -Poliomyelitis -.ppt
 
4C. VIRAL CNS INFECTIONS -POLIO, RABIES.pptx
4C. VIRAL CNS INFECTIONS -POLIO, RABIES.pptx4C. VIRAL CNS INFECTIONS -POLIO, RABIES.pptx
4C. VIRAL CNS INFECTIONS -POLIO, RABIES.pptx
 
routine immunization in india( from gov.in) .ppt
routine immunization in india( from gov.in) .pptroutine immunization in india( from gov.in) .ppt
routine immunization in india( from gov.in) .ppt
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
EPIDEMIOLOGY – COMMUNICABLE DISEASE.pptx
EPIDEMIOLOGY – COMMUNICABLE DISEASE.pptxEPIDEMIOLOGY – COMMUNICABLE DISEASE.pptx
EPIDEMIOLOGY – COMMUNICABLE DISEASE.pptx
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
MEASLES - THEORY.ppt
MEASLES - THEORY.pptMEASLES - THEORY.ppt
MEASLES - THEORY.ppt
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
7.Poliomyelitis (1).ppt7.Poliomyelitis (1)
7.Poliomyelitis (1).ppt7.Poliomyelitis (1)7.Poliomyelitis (1).ppt7.Poliomyelitis (1)
7.Poliomyelitis (1).ppt7.Poliomyelitis (1)
 
Picornavirus
PicornavirusPicornavirus
Picornavirus
 
Acute flaccid paralysis
Acute flaccid paralysisAcute flaccid paralysis
Acute flaccid paralysis
 
Meningitis In Children
Meningitis  In ChildrenMeningitis  In Children
Meningitis In Children
 
Surface infection
Surface infectionSurface infection
Surface infection
 
Geriatric health communicable diseases and Egypt
Geriatric health communicable diseases and EgyptGeriatric health communicable diseases and Egypt
Geriatric health communicable diseases and Egypt
 
ANNUAHREE's presentation.pptx
ANNUAHREE's presentation.pptxANNUAHREE's presentation.pptx
ANNUAHREE's presentation.pptx
 
Meningococcal meningitis
Meningococcal meningitisMeningococcal meningitis
Meningococcal meningitis
 
Poliomyelitis in english
Poliomyelitis in englishPoliomyelitis in english
Poliomyelitis in english
 

More from KULDEEP VYAS

Unit - 13 Patient Education.pdf
Unit - 13 Patient Education.pdfUnit - 13 Patient Education.pdf
Unit - 13 Patient Education.pdf
KULDEEP VYAS
 
RESTRAINTS.pptx
RESTRAINTS.pptxRESTRAINTS.pptx
RESTRAINTS.pptx
KULDEEP VYAS
 
FALL RISK ASSESSMENT.pptx
FALL RISK ASSESSMENT.pptxFALL RISK ASSESSMENT.pptx
FALL RISK ASSESSMENT.pptx
KULDEEP VYAS
 
Unit 10 Promoting Safety in Health Care Enevronment (FON).pdf
Unit 10 Promoting Safety in Health Care Enevronment (FON).pdfUnit 10 Promoting Safety in Health Care Enevronment (FON).pdf
Unit 10 Promoting Safety in Health Care Enevronment (FON).pdf
KULDEEP VYAS
 
Florence Nightingle PPT.pptx
Florence Nightingle PPT.pptxFlorence Nightingle PPT.pptx
Florence Nightingle PPT.pptx
KULDEEP VYAS
 
Fluorosis
FluorosisFluorosis
Fluorosis
KULDEEP VYAS
 
SARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern OmicronSARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern Omicron
KULDEEP VYAS
 
Evaluation
EvaluationEvaluation
Evaluation
KULDEEP VYAS
 
Human resource management in hospital and community services
Human resource management in hospital and community servicesHuman resource management in hospital and community services
Human resource management in hospital and community services
KULDEEP VYAS
 
Emergency and disaster management new
Emergency and disaster management newEmergency and disaster management new
Emergency and disaster management new
KULDEEP VYAS
 
Maintenance of Discipline
Maintenance of DisciplineMaintenance of Discipline
Maintenance of Discipline
KULDEEP VYAS
 
Evaluation
EvaluationEvaluation
Evaluation
KULDEEP VYAS
 
Nursing Standards and Policies
Nursing Standards and PoliciesNursing Standards and Policies
Nursing Standards and Policies
KULDEEP VYAS
 
Supervision and guidance
Supervision and guidanceSupervision and guidance
Supervision and guidance
KULDEEP VYAS
 
Assignmant,rotation and deligation
Assignmant,rotation and deligationAssignmant,rotation and deligation
Assignmant,rotation and deligation
KULDEEP VYAS
 
Directing leading in hospital and community services
Directing leading in hospital and community servicesDirecting leading in hospital and community services
Directing leading in hospital and community services
KULDEEP VYAS
 
Commonly used Insecticides and Pesticides
Commonly used Insecticides and Pesticides Commonly used Insecticides and Pesticides
Commonly used Insecticides and Pesticides
KULDEEP VYAS
 
Material management in hospital and community services
Material management in hospital and community servicesMaterial management in hospital and community services
Material management in hospital and community services
KULDEEP VYAS
 
Budgeting for Hospital and Community
Budgeting  for  Hospital and CommunityBudgeting  for  Hospital and Community
Budgeting for Hospital and Community
KULDEEP VYAS
 
Patient population assessment
Patient population  assessment Patient population  assessment
Patient population assessment
KULDEEP VYAS
 

More from KULDEEP VYAS (20)

Unit - 13 Patient Education.pdf
Unit - 13 Patient Education.pdfUnit - 13 Patient Education.pdf
Unit - 13 Patient Education.pdf
 
RESTRAINTS.pptx
RESTRAINTS.pptxRESTRAINTS.pptx
RESTRAINTS.pptx
 
FALL RISK ASSESSMENT.pptx
FALL RISK ASSESSMENT.pptxFALL RISK ASSESSMENT.pptx
FALL RISK ASSESSMENT.pptx
 
Unit 10 Promoting Safety in Health Care Enevronment (FON).pdf
Unit 10 Promoting Safety in Health Care Enevronment (FON).pdfUnit 10 Promoting Safety in Health Care Enevronment (FON).pdf
Unit 10 Promoting Safety in Health Care Enevronment (FON).pdf
 
Florence Nightingle PPT.pptx
Florence Nightingle PPT.pptxFlorence Nightingle PPT.pptx
Florence Nightingle PPT.pptx
 
Fluorosis
FluorosisFluorosis
Fluorosis
 
SARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern OmicronSARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern Omicron
 
Evaluation
EvaluationEvaluation
Evaluation
 
Human resource management in hospital and community services
Human resource management in hospital and community servicesHuman resource management in hospital and community services
Human resource management in hospital and community services
 
Emergency and disaster management new
Emergency and disaster management newEmergency and disaster management new
Emergency and disaster management new
 
Maintenance of Discipline
Maintenance of DisciplineMaintenance of Discipline
Maintenance of Discipline
 
Evaluation
EvaluationEvaluation
Evaluation
 
Nursing Standards and Policies
Nursing Standards and PoliciesNursing Standards and Policies
Nursing Standards and Policies
 
Supervision and guidance
Supervision and guidanceSupervision and guidance
Supervision and guidance
 
Assignmant,rotation and deligation
Assignmant,rotation and deligationAssignmant,rotation and deligation
Assignmant,rotation and deligation
 
Directing leading in hospital and community services
Directing leading in hospital and community servicesDirecting leading in hospital and community services
Directing leading in hospital and community services
 
Commonly used Insecticides and Pesticides
Commonly used Insecticides and Pesticides Commonly used Insecticides and Pesticides
Commonly used Insecticides and Pesticides
 
Material management in hospital and community services
Material management in hospital and community servicesMaterial management in hospital and community services
Material management in hospital and community services
 
Budgeting for Hospital and Community
Budgeting  for  Hospital and CommunityBudgeting  for  Hospital and Community
Budgeting for Hospital and Community
 
Patient population assessment
Patient population  assessment Patient population  assessment
Patient population assessment
 

Recently uploaded

Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Yodley Lifesciences
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
NEHA GUPTA
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
SwastikAyurveda
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
Suraj Goswami
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 

Recently uploaded (20)

Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 

Poliomyelitis

  • 1. POLIOMYELITIS Kuldeep Vyas Asst. Prof. Community Health Nursing1Kuldeep Vyas M.Sc. N. CHN
  • 2. Introduction  Greek poliós= "grey", myelós= marrow, and the suffix - itis= inflammation  First described by British physician Micheal Underwood in 1799 referring to it as "debility of the lower extremities.“  A viral infection most often recognized by acute onset of flaccid paralysis.  Primarily an infection of human alimentary tract, but may infect CNS in very small no. (i.e <1%)  Infection results in a spectrum of clinical manifestations…… 2Kuldeep Vyas M.Sc. N. CHN
  • 4. Problem statement World  A worldwide problem in pre vaccination era  With the wide use of polio vaccine from 1954 disease being eliminated from most of the developed countries  In 1988 WHA resolved to eradicate the disease globally  Since than no. of endemic countries reduced from 125 in 1988 to 3 in 2012.  Reported cases worldwide decreased by 51% (1352 in 2010 to 650 in 2011) 4Kuldeep Vyas M.Sc. N. CHN
  • 5. Cont… India No reported cases since January 2011 (last case reported in 13th Jan 2011, Howrah, West Bengal) Considered polio-free since February 2012 Attained the status of eradication in 13th January 2014 5Kuldeep Vyas M.Sc. N. CHN
  • 7. Agent factors Agent Poliovirus: belongs to “Picorna” viruses which are small RNA-containing viruses. Three serotypes- 1, 2 & 3 giving no cross immunity Long survival in environment….lives upto 4hours in water and 6 hours in faeces in cold enviornment. Readily destroyed by heat (e.g. pasteurization of milk, and chlorination of water). 7Kuldeep Vyas M.Sc. N. CHN
  • 8. Reservoir of infection  Man is the only reservoir of infection of poliomyelitis.  Man: cases and carriers  Cases: all clinical forms of disease  Most of the infections are subclinical- dominant role in spread of infection  Estimated subclinical infection ranges from 75 to 1000 per clinical case  No chronic cases or animal sources documented Foci of infection  Pharynx: the virus is found in the oropharyngeal secretions.  Small intestine: the virus finds exit in stools. 8Kuldeep Vyas M.Sc. N. CHN
  • 9. Modes of transmission Since foci of infection are the throat and small intestines, poliomyelitis spreads by two routes: Oral-oral infection: direct droplet infection Faeco-oral infection: – Through contaminated foods. Vehicles include milk, water, or any others that may be contaminated by handling, flies, dust…. – Hand to mouth infection. Polio virus has the ability to survive in cold environments. Overcrowding and poor sanitation provide opportunities for exposure to infection 9Kuldeep Vyas M.Sc. N. CHN
  • 10. Period of communicability  Estimated to about 2 weeks  Cases: 7 to 10 days before and after the onset of symptoms.  Virus is excreted commonly for 2 to 3 weeks, sometimes as long as 3 to 4 months in faeces.  In polio cases, infectivity in the pharyngeal foci is around one week, and in the intestinal foci 6-8 weeks. Incubation Period: 7-14 days 10Kuldeep Vyas M.Sc. N. CHN
  • 11. Host factors Age:  All age groups; children(6 MONTHS TO 3 YEARS most susceptible)  more than 95% reported in infancy and childhood with over 50% of them in infancy. Sex:  no sex ratio differences, but in some countries, males are infected more frequently than females in a ratio 3:1. Risk factors:  Fatigue, trauma,im injections, tonsillectomy, immunizing agents like alum containing DPT vaccine and excessive muscular exercise… Immunity:  Immunity by maternal antibodies till the age of 6months  Immunity conferred by natural infection fairly solid but doesn’t protects against the reinfection by other strains 11Kuldeep Vyas M.Sc. N. CHN
  • 12. Environmental factors Rainy season (june to september) Environmental sources- food, flies and water Overcrowding and poor sanitation- oppourtinities 12Kuldeep Vyas M.Sc. N. CHN
  • 14. Inapparent infection  Occurs approximately in 91-96% of poliovirus infection.  Incidence is more than 75 to 1000 times the clinical cases.  No clinical manifestations, but infection is associated with acquired immunity.  Recognition only by virus isolation or rising antibody titre. 14Kuldeep Vyas M.Sc. N. CHN
  • 15. Clinical poliomyelitis Abortive polio (minor illness):  Occurs approximately in 4-8% of the infection.  Causes only a mild or self limiting illness due to viraemia.  Mild systemic manifestations for 1-2 days  Some abortive cases so mild to pass unnoticed.  Patient recovers quickly.  Manifestations:  Moderate fever  Upper respiratory manifestations: pharyngitis and sore throat  Gastrointestinal manifestations: vomiting, abdominal pain, and diarrhea. 15Kuldeep Vyas M.Sc. N. CHN
  • 16. Cont….. Involvement of the CNS (major illness):  Affects a small proportion of the clinical cases  Takes two forms: Non-paralytic and Paralytic polio. Non paralytic polio:  Occurs approximately in one per cent of all infections.  Presenting features are stiffness and pain in neck and back.  Disease lasts for 2-10 days.  Recovery is rapid. 16Kuldeep Vyas M.Sc. N. CHN
  • 17. Cont… Paralytic polio:  Occurs in less then one per cent of infections.  The virus enters the CNS and causes varying degree of disability with destruction of the motor nerve cells, but not the sensory nerve cells.  Forms: spinal, bulbar, and bulbospinal.  Paralysis usually appears within 4 days (around 7-10 days from onset of disease).  History of fever at the time of paralysis- suggestive of polio.  Progression of paralysis reaches maximum by 4th day (4-7 days) 17Kuldeep Vyas M.Sc. N. CHN
  • 18. Cont….  Other symptoms- malaise, anorexia, vommiting, headache, sore throat, constipation and headache.  Signs of meningeal irritation  Tripod sign may be present  Assymetrical, patchy flaccid paralysis, of descending type affecting the proximal group of muscle the most  Deep tendon reflexes (DTR) deminished before the the onset of paralysis.  Cranial nerve involvement seen in bulbar and bulbospinal paralytic poliomyelitis  Facial assymetry, difficulty in swallowing weakness of voice; respiratory insuffiency may lead to death 18Kuldeep Vyas M.Sc. N. CHN
  • 20. Spinal polio Different spinal nerves are involved Injury of the anterior horn cells of the spinal cord causing tenderness, weakness, and flaccid paralysis of the corresponding striated muscles. The lower limbs are the most commonly affected. 20Kuldeep Vyas M.Sc. N. CHN
  • 21. Bulbar polio Nuclei of the cranial nerves are involved, causing weakness of the supplied muscles, and maybe encephalitis. Bulbar manifestations include dysphagia, nasal voice, fluid regurgitation from the nose, difficult chewing, facial weakness and diplopia Paralysis of the muscles of respiration is the most serious life-threatening manifestation. Bulbospinal polio  Combination of both spinal and bulbar forms 21Kuldeep Vyas M.Sc. N. CHN
  • 22. Polio infection Polio infection Inapparent infection Clinical poliomyelitis Abortive polio Involvement of CNS (minor illness) (major illness) Paralytic polio Non-paralytic polio Spinal polio Bulbar polio Bulbospinal polio 22Kuldeep Vyas M.Sc. N. CHN
  • 23. Complications and case fatality  Respiratory complications: pneumonia, pulmonary edema  Cardiovascular complications: myocarditis, cor pulmonale.  Late complications: soft tissue and bone deformities, osteoporosis, and chronic distension of the colon.  Case fatality: varies from 1% to 10% according to the form of disease (higher in bulbar), complications and age ( fatality increases with age). 23Kuldeep Vyas M.Sc. N. CHN
  • 24.  Polio is caused by a virus called polio virus 24Kuldeep Vyas M.Sc. N. CHN
  • 25. Virus gets into the body by mouth Then moves to GI Track towards intestine Multiplies Passes into the blood Reaches the spinal cord Attacks the nerves Destruction of motor neurons of brain stem Result in polio paralysis 25Kuldeep Vyas M.Sc. N. CHN
  • 26. Diagnosis and laboratory testing Laboratory studies critical to rule out or confirm the diagnosis of paralytic poliomyelitis.  Virus isolation  The likelihood of poliovirus isolation is highest from stool specimens,  Intermediate from pharyngeal swabs, and very low from blood or spinal fluid.  Serologic testing A four-fold titer rise between the acute and convalescent specimens suggests poliovirus infection. 26Kuldeep Vyas M.Sc. N. CHN
  • 27. Prevention General prevention: Health promotion through environmental sanitation. Health education (modes of spread, protective value of vaccination). 27Kuldeep Vyas M.Sc. N. CHN
  • 28. Cont…. Seroprophylaxis by immunoglobulins: Not a practical way of giving protection because it must be given either or before or very shortly after exposure to infection. Dose-(0.25-0.3 ml/kg of body weight). Immunized status after a few weeks 28Kuldeep Vyas M.Sc. N. CHN
  • 29. Active immunization Inactivated (Salk) vaccine (FIPV)  Contains 3 serotypes of vaccine virus  Route of administration- Intra-dermal: Right upper arm .  Schedule  First dose given at the age of 6 weeks  Second dose given at the 14 weeks of age  Intra dermal two fractional dose of : 0.1 ml  Highly effective in producing immunity to poliovirus  >90% immune after 1 doses  >99% immune after 2 doses  Duration of immunity not known with certainty 29Kuldeep Vyas M.Sc. N. CHN
  • 30. Cont… Oral (Sabin) Polio Vaccine  Contains 3 serotypes of vaccine virus  Route of administration- Oral.  Schedule  Zero dose vaccination recommended in hospital delivery  First dose given at the age of 6 weeks  Next 2 doses 10 weeks  3rd dose at 14 weeks  2 drops  Highly effective in producing immunity to poliovirus  50% immune after 1 dose  >95% immune after 3 doses  Immunity probably lifelong  Shed in stool for up to 6 weeks following vaccination 30Kuldeep Vyas M.Sc. N. CHN
  • 32. Salk versus Sabin vaccine 32Kuldeep Vyas M.Sc. N. CHN
  • 33. ORAL POLIO VACCINE OPV INACTIVATED POLIO VACCINE IPV Albert sabin develop sabin vaccine Jonas salk developed salk vaccine Live, attenuated (weakened) virus Killed virus Administered by drops Administered by injection Highly successful in reducing transmission in developing countries as part of eradication strategy Highly effective and safe; Used in developed countries Inexpensive Expensive 33Kuldeep Vyas M.Sc. N. CHN
  • 34. Easy to administer Requires trained health care worker Provides humoral, mucosal and gut immunity Provides humoral immunity Prevents paralysis and prevents re-infection Prevents paralysis but does not prevent re-infection Dose = 2 drops Dose = 0.5 ml Recommended storage temperature= -15֯C to - 25֯C Storage temperature= +2֯C to +8֯C 34Kuldeep Vyas M.Sc. N. CHN
  • 35. Epidemiological Investigations Epidemic  Occurrence of 2 or more local cases caused by the same virus in any 4-weeks period  Sample of faeces to be collected from all the cases and suspected cases and subjected to lab testing  If possible, paired sera to be tested – First specimen at the clinical suspicion – Second at the period of convalescence  An increase in antibody titre provides confirmatory evidence  OPV should be provided to all persons over 6 weeks age who are not completely immunize de or immune status unknown in the epidemic area 35Kuldeep Vyas M.Sc. N. CHN